ALK and non-small cell lung carcinoma: The ROS-1 gene has 49% sequence homology in the kinase domain and 77% identity at the ATP-binding site with anaplastic lymphoma kinase (ALK), thereby forming the basis for the utilization of ALK inhibitors for ROS-1 rearranged NSCLC patients [10].